Kornimate/medical-research-clean huggingface dataset:
the impact of lorazepam on cognition in apoe e4 carriers

Conditions: Alzheimer's Disease

Summary: we expect the results of this pilot study to justify a larger study that follows people to determine if certain tests of memory and attention, performed while sleepiness is induced by a single dose of lorazepam (a widely used anti-anxiety medication) could predict an individual's risk of developing ad. we plan to compare cognitively normal people who possess a common gene that increases risk for ad- the apolipoprotein e (apoe) e4 allele-to individuals without this gene. we hypothesize that a single 2 mg dose of lorazepam will cause more cognitive impairment in carriers of the apoe e4 allele than in noncarriers, and that the carriers will recover more slowly from these impairments than noncarriers.

we aim to compare measures of memory and information processing speed at 2.5 hours and 5 hours after the administration of a 2 mg dose of lorazepam or placebo in cognitively normal, 50-65 year old apoe e4 carriers and noncarriers, and determine the differential impact of lorazepam on cognition at each time point. twenty carriers and 20 noncarriers matched for age, sex, and education will be drawn from a database of persons who have already undergone genotyping for an ongoing study at the mayo clinic, excluding people with evidence of depression or cognitive impairment and other medical, neurological or psychiatric conditions. using a double blind, crossover design, subjects will receive either placebo or a 2 mg dose of lorazepam after baseline testing. equivalent tests will be repeated 2.5 and 5 hours post challenge. the data analysis will compare apoe e4 carriers to noncarriers.

Eligibility criteria:
inclusion criteria: * a score of at least 28 on the mmse * a score of less than 10 points on the ham-d-17 * age 50-65 * genotype apoe e3/e4 or apoe e4 non-carriers * cognitively normal exclusion criteria: * significant medical, psychiatric, or neurological illnesses * use of benzodiazepines within the previous four weeks * currently using sedating antihistamines

Keywords: apolipoprotein e e4 alzheimer's disease somnolence early detection
the collateral impact of bariatric surgery on families

Conditions: Obesity; Bariatric Surgery Candidate; Weight Loss

Summary: this proposal is designed to examine the impact of bariatric surgery on the health of patients and their families. the shared environment of spouses/cohabitating partners suggests that patients' families are exposed to the extensive diet and lifestyle changes required of patients following bariatric surgery.

the specific aims of this proposal are to: 1. collect clinical data (e.g., weight, blood pressure, body composition, blood sample), as well as monitor physical activity and eating patterns, before and after bariatric surgery (adults only). 2. analyze clinical data, physical activity and eating patterns to determine how the health of patients and their families change after one family member completes bariatric surgery (adults only). 3. determine the feasibility of recruiting patients, spouses/partners and their children.

Eligibility criteria:
inclusion criteria: * all patients who receive surgery have been cleared medically and psychosocially for surgery. thus, surgical candidacy criteria will serve as eligibility criteria for the current study for surgical patients. * cohabitation with patients will be considered inclusion criteria for partners/spouses. * children between the ages of ≥5 - ≤ 16, who cohabitate with the patient the majority of the time will be asked to participate by providing assent. exclusion criteria: * report current or planned use of weight loss medications (including otc), or other weight loss strategy. * report pregnancy, lactation, or plans to become pregnant during study duration.

Keywords: obesity bariatric surgery weight loss physical activity body composition
effects of an aerobic exercise intervention on core symptoms, executive functioning, and quality of life in children with attention deficit hyperactivity disorder

Conditions: ADHD

Summary: selecting a maternal and child healthcare hospital in shenzhen city, guangdong province, 50 cases of adhd children as the study subjects, according to the inclusion and exclusion criteria to screen the eligible study subjects, introduction of the purpose and process of the study, informed consent to enrolment, the children were divided into the intervention group and the control group. the experimental group used aerobic exercise, while the control group was given daily physical activity, and general information questionnaires, conners parental symptom questionnaire, snap-iv scale, stroop colour word test, rey complex graphics test, connection test, children's depressive disorder self-assessment scale, children's anxious mood disorder screening scale, children's quality of life universal core scale, and children's executive functioning questionnaire were assessed.

purposive sampling method was used to select a maternal and child healthcare hospital in shenzhen city, guangdong province, 50 cases of adhd children as the study subjects, according to the inclusion and exclusion criteria to screen the eligible study subjects, introduction of the purpose and process of the study, informed consent to enrolment, the children were divided into age, gender, clinical typing, medication use, family proximity, conners scores and snap-iv scores matching the intervention group and the control group. the experimental group used aerobic exercise, while the control group was given daily physical activity, and general information questionnaires, conners parental symptom questionnaire, snap-iv scale, stroop colour word test, rey complex graphics test, connection test, children's depressive disorder self-assessment scale, children's anxious mood disorder screening scale, children's quality of life universal core scale, and children's executive functioning questionnaire were assessed.

Eligibility criteria:
inclusion criteria: * children clinically diagnosed with adhd; * 7-14 years old; * combined raven's test ≥ 80; * not participating in any treatment other than drug therapy; * the body can participate in sports training; * the type of family intimacy is intimate or above; * voluntarily participate and sign an informed consent form exclusion criteria: * children with a history of epileptic seizures; * children with other mental or motor disorders; * children with visual impairments; * using other psychotropic drugs; * have other comorbidities; * merge other serious chronic diseases (such as severe heart, brain, kidney, lung, etc.), tumors, etc
exploration the mechanism of ba-duan-jin in the treatment of fibromyalgia based on brain-gut axis

Conditions: Fibromyalgia

Summary: to investigate the mechanism by ba-duan-jin in the treatment of fibromyalgia. twenty eligible fibromyalgia patients were selected, and were trained and guided online by an experienced ba-duan-jin instructor with reference to the standard operating procedure (sop) for a 12-week course of 1 hour twice a week. the evaluation points were 0, 4, 8, and 12 weeks. the change of pain visual analogue score (vas) and tener point count (tpc) post-treatment were evaluated. and blood, feces, and brain fmri were collected from the patients at 0 and 12 weeks to compare the changes in gut microbiota, metabolites, and brain function networks before and after the intervention with the 16srrna sequencing, targeted metabolomics, and real-time quantitative polymerase chain reaction (pcr).


Eligibility criteria:
inclusion criteria: * meet the 1990 american college of rheumatology (acr) research classification criteria for fibromyalgia or 2016 revisions to the 2010/2011 fibromyalgia diagnostic criteria; * be over 18 years of age; * female; * right-handedness; * sign informed consent. exclusion criteria: * be less than 40mm of pain vas score; * had received any treatments for fibromyalgia or probiotic bacteria within 2 weeks; * had received antibiotics within 4 weeks; * had practiced ba-duan-jin, tai chi, yoga, or other forms of qigong within previous 12 months; * had severe depression or anxiety; * pregnancy or planned pregnancy within the study period; * had any poorly-controlled comorbid medical conditions, such as dementia, cancer, thyroid disease, inflammatory arthritis; * patients with a history of head trauma, cerebral infarction or cerebral haemorrhage * contraindications for mri,including metal implants, cardiac pacemaker,false tooth, surgical artery clips, metal tattoos or claustrophobia;
selecting specific bio-markers and researching mechanisms of immune regulation from inhalation injury and traumatic lung injury based on single cell sequencing technology

Conditions: Traumatic Lung Injury; Inhalation Injury

Summary: the goal of this observational study is to profile the circulating immunological traits of patients with traumatic lung injury (tli) and inhalation injury (ili),providing a new direction for the depth research of the pathogenesis, and providing new immune-related targets for diagnosis of the severity of lung injury and treatment. the investigators performed scrna-seq of neutrophil and peripheral blood mononuclear cells (pbmcs) from 10 ml fresh circulating blood from 3 patients with tli and 3 patients with ili at longitudinal timepoints,as well as peripheral blood from 3 health controls(hcs).

the investigators performed single-cell transcriptomic sequencing (bd rhapsody) on neutrophil and pbmcs extracted from the fresh circulating blood from 3 patients with tli and 3 patients with ili at longitudinal timepoints,as well as peripheral blood from 3 health controls(hcs). three time points are picked by clinical conditions of patients with tli or ili: day 1 post hospital admission, day 3 post hospital and the day before discharged which matched to acute stage,progressive stage and convalescence.

Eligibility criteria:
inclusion criteria: 1. lung injury caused by burn trauma is confirmed, and the patient is hospitalized within 24 hours after burn or trauma (the clinician can make a definite diagnosis of lung injury based on the comprehensive judgment of the patient's etiology, history, clinical manifestations, blood gas analysis, laboratory tests and imaging); 2. patients with inhalation injury caused by head, face and neck burns or inhalation injury combined with multiple body burns \< 30%; 3. patients with simple inhalation injury; 4. the normal control group should have no smoking history and be normal population; 5. according to the provisions of good clinical practice(gcp), the informed consent has been obtained and the informed consent has been signed to volunteer for the test. exclusion criteria: 1. basic pulmonary diseases like chronic obstructive pulmonary disease (copd), asthma and et al; 2. severe organ dysfunction; 3. autoimmune diseases; 4. tumor; 5. severe infection; 6. pregnant or nursing women; 7. fatal or life-threatening events caused by trauma; 8. any history which may interfere the results or increase the risk of patients judged by researchers.
study of belimumab administered subcutaneously to healthy subjects

Conditions: Healthy

Summary: the purpose of this study is to measure the amount of belimumab in the blood when given as an injection under the skin (subcutaneously; sc) and to evaluate the safety and tolerability of multiple injections under the skin in healthy subjects.

this study is designed to evaluate the absolute bioavailability, pharmacokinetics, tolerability, and safety of a single dose (groups 1-4) or multiple doses (groups 5-6) of belimumab administered subcutaneously (sc) to healthy subjects.

Eligibility criteria:
key inclusion criteria: * healthy subjects defined as no clinically relevant abnormalities identified by a detailed medical history, full physical exam, 12-lead electrocardiogram (ecg), and clinical laboratory tests. * body weight between 45 to 120 kg (99 to 264 lbs). * must agree to use effective contraception throughout the study and for 14 weeks after administration of belimumab. * have the ability to understand the requirements of the study, provide written informed consent, and comply with the study protocol procedures. key exclusion criteria: * pregnant or nursing. * test positive for drugs or alcohol or have had a drug or alcohol dependence within the past year. * have used any prescription medicines within the past 30 days or herbal/botanical supplements within the past 7 days or anticipate use during the study. may use prescription contraceptives, hormone replacement therapy, and over-the-counter medicines such as antihistamines or nutritional support such as vitamins, minerals, or amino acids. * have received a live vaccine within the past 30 days or anticipate receipt of a live vaccine during the study and within 4 months after last injection of belimumab. * have a history of an allergic or anaphylactic reaction to drugs, food, or insect bite or sting requiring medical intervention. * have a history of allergic reaction to contrast agents or biological medicines. * have participated in a clinical trial and received an experimental medicine within the past 60 days. * have received treatment with a b cell targeted therapy at any time. * have required management of an infection within the past 14 days.

Keywords: belimumab injections, subcutaneous drug administration routes injections lupus erythematosus, systemic lupus sle systemic lupus erythematosus antibodies autoimmune disease biological therapy immune system diseases pharmacokinetics biological availability
efficiency, and emergency department nurse preference between 2 methods of visualization: a pilot study

Conditions: Catheter Related Complication

Summary: the purpose of this study was to assess the impact of a continuous needle tracking system on the accuracy, speed, and quality of ultrasound-guided peripheral venous catheter insertion.

a pilot study using simulated tissue was conducted with 49 us-based emergency department nurses to compare insertion of a midline catheter using traditional ultrasound guidance versus an advanced needle-tracking technology along with traditional ultrasound guidance.

Eligibility criteria:
inclusion criteria: * us-based emergency department nurse who have placed 10 peripheral intravenous catheters in the past 60 days * have placed less than or equal to 15 ultrasound-assisted vascular access devices in the past 60 days and have been practicing ultrasound-assisted vascular access no more than 18 months exclusion criteria: * nurses that don't meet that predetermined inclusion criteria

Keywords: visualization needle guidance midline catheter emergency department nurse
accuracy of corneal astigmatism in different region modes

Conditions: Astigmatism; Cornea

Summary: to analyze the difference between measured total corneal astigmatism and actual corneal astigmatism under different region modes and optimize the region setting.


Eligibility criteria:
inclusion criteria: * age ≥ 18 years * patients who had received phacoemulsification surgery with or without implantation of toric iol are with a certain amount of corneal astigmatism. * best corrected visual acuity ≥ 0.66 (20/30 snellen) exclusion criteria: * corneal diseases or severe irregular astigmatism (e.g., pterygium, keratoconus), existence of corneal opacification; * ocular disease which may affect visual acuity (e.g., glaucoma, uveitis, retinal disease, pathologic myopia); * history of ocular surgery or ocular trauma before this cataract surgery; * decentration of iol \> 0.3mm or tilt \> 5° * implantation of multifocal iol * history of wearing of rigid contact lens within the past 4 weeks or soft contact lens within 1 week;

Keywords: corneal astigmatism scheimpflug pupil size toric
perceptual-cognitive training after a mild traumatic brain injury: towards a sensitive marker for recovery

Conditions: Brain Concussion; Post-Concussion Symptoms; Concussion

Summary: this study is part of a larger, multi-centered project done with the collaboration of university of victoria. this study holds three separate studies on the mild traumatic brain injured population and the use of perceptual-cognitive training (3d-mot).


Eligibility criteria:
inclusion criteria: * the child experienced a head injury (a direct or indirect blow to the head) resulting in concussion-like symptoms (e.g. headache, nausea, balance problems, tiredness, visual problems, cognitive issues) in the previous 72 hours * parent/legal guardian speak english or french * the child speak english or french exclusion criteria: * previous concussion in the last 6 months, or any previous concussion with unresolved symptoms * multi-system injuries requiring admission, operating room, procedural sedation in the emergency department * other co-existing injuries, co-morbidities or diagnoses preventing participation to intervention/assessment of gait and balance * pre-morbid or co-morbid condition affecting visual function * patient intoxicated at the time of injury * significant developmental delay * loss of consciousness prior to head injury
regional or extend lymphadenectomy during resection of intrahepatic cholangiocarcinoma

Conditions: Intrahepatic Cholangiocarcinoma

Summary: intrahepatic cholangiocarcinoma (icc) is one of the common malignant tumors. lymph node metastasis is an important factor affecting the poor prognosis of intrahepatic cholangiocarcinoma. the eighth edition of the ajcc guidelines recommends at least 6 lymph nodes to be used for staging. the american hepatobiliary and pancreatic association also recommends the removal of hilar lymph nodes as part of the radical surgery for intrahepatic cholangiocarcinoma. however, some scholars have found that patients with regional lymph nodes have similar survival rates. this contradictory result has prompted more scholars to conduct clinical research to explore the necessity and standardization of lymph node dissection in intrahepatic cholangiocarcinoma.

expanding lymph node dissection can theoretically obtain more lymph node dissection. obtaining enough lymph nodes can improve the accuracy of ajcc staging and accurately determine prognosis. however, it is unclear whether it will improve the prognosis of patients with lymph node dissection. according to literature reports and related studies, expanded lymph node dissection for right liver tumors included stations 12, 8, and 13, and left lymphoma expanded lymph node dissection includedstations 12, 1, 3, 7, and 8. in summary, standardize the extent of lymph node dissection in intrahepatic cholangiocarcinoma, and obtain enough lymph node dissection under the premise of controlling the complication rate, which is helpful for accurate tnm staging, accurate judgment of prognosis and improvement of survival time. improve prognosis.

Eligibility criteria:
inclusion criteria: * patients \>18 years of age and ≤80 years of age; * preoperative imaging and laboratory examination for intrahepatic cholangiocarcinoma, intraoperative frozen and postoperative pathology confirmed as intrahepatic cholangiocarcinoma; preoperative imaging assessment is resectable; * no obvious lymph node metastasis in preoperative imaging; or negative intraoperative lymph node biopsy * liver function child-turcotte-pugh score a-b grade; * residual liver volume \>30%; can tolerate radical hepatectomy * the patient has autonomy, understands and voluntarily signs the written informed consent and is able to complete the follow-up plan; * sign the written informed consent form prior to the test screening. exclusion criteria: * the patient has obvious heart, lung, brain and kidney dysfunction that affects the treatment of intrahepatic cholangiocarcinoma; * the patient has a history of other malignant tumors; * liver function child-turcotte-pugh score c; * the investigator determined that it was not suitable for the study.
virtual celiac symptoms study in adults and teenagers

Conditions: Celiac Disease

Summary: the goal of this study is to better understand the symptoms and impacts of celiac disease (ced). participants use a smart phone online app to answer daily questionnaires about symptoms and life with ced for 12 weeks. there are no blood draws, gluten challenges, medications, or doctor visits required.

this is an observational, prospective study to measure symptoms and impacts of ced. this study will assess ced symptom patterns over a 3-month observation period. the study will enroll approximately 400 participants. the data will be prospectively collected, via a self-reported epro platform accessible by smartphone. this virtual study will be conducted in the united states.

Eligibility criteria:
inclusion criteria: 1. at least 12 years of age or older. 2. diagnosed with ced for at least 1 year. 3. for participants diagnosed over the age of 18: biopsy confirmed diagnosis with ced (participant reported). 4. for participants diagnosed under the age of 18: blood test or biopsy confirmed diagnosis with ced (participant reported). 5. currently following a gluten free diet (gfd) for at least 6 months. 6. has experienced symptoms believed by the participant to be ced related in the last 3 months. 7. has daily access to a smartphone as well as internet/wi-fi/cellular data. 8. speaks and reads english. 9. lives in the us (participant reported). exclusion criteria: 1. currently involved or planning to be involved in any clinical studies with an investigational drug, surgical procedure, or gluten challenge over the 3-month observation period.

Keywords: celiac disease signs and symptoms digestive quality of life diet gluten-free
a study of chemoradiation in combination with tislelizumab as first line treatment in participants with advanced esophageal squamous cell carcinoma

Conditions: Esophageal Squamous Cell Carcinoma

Summary: this study is a multicentre, randomised, parallel-controlled, open-label, 3 phase clinical trial. the subjects were untreated, unresectable locally advanced, recurrent or metastatic esophageal squamous cell carcinoma with low pd-l1 expression. patients were randomly assigned to receive chemoradiation or chemotherapy in combination with tislelizumab at a ratio of 1: 1. the primary endpoint was progression-free survival (pfs) in the intention-to-treat population. we hypothesized that in advanced esophageal squamous cell carcinoma patients with low pd-l1 expression, chemoradiation versus chemotherapy in combination with tislelizumab will significantly improve pfs.


Eligibility criteria:
inclusion criteria: 1. subjects must have histologically confirmed squamous cell carcinoma of esophagus (per ajcc 8th edition). 2. subjects must have unresectable advanced, recurrent or metastatic escc. 3. subjects must not be amenable to curative approaches such as definitive chemoradiation and/or surgery. 4. pd-l1 expression (cps) is less than 10. 5. no prior systemic anticancer therapy given as primary therapy for advanced or metastatic disease. 6. ecog performance status of 0 or 1. 7. subjects must have at least one measurable lesion by ct or mri per recist 1.1 criteria; radiographic tumor assessment must be performed within 28 days prior to randomization. 8. subjects must have adequate organ and bone marrow function. exclusion criteria: 1. presence of tumor cells in the brain or spinal cord which are symptomatic or require treatment. 2. active known or suspected autoimmune disease. 3. any serious or uncontrolled medical disorder or active infection. 4. known history of positive test for human immunodeficiency virus (hiv) or known acquired immunodeficiency syndrome (aids). 5. any positive test result for hepatitis b or c indicating acute or chronic infection and/or detectable virus. 6. prior treatment with an anti-pd-1, anti-pd-l1, anti-pd-l2, anti-cd137, or anti-ctla-4 antibody, or any other antibody or drug specifically targeting t-cell co-stimulation or checkpoint pathways.

Keywords: chemoradiation immunotherapy advanced esophageal cancer low pd-l1 expression progression-free survival